This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Need Learning Now?

Join us for this free-to-attend webinar series June 8-10 featuring 8 live scientific demonstrations presented by leading scientists and researchers to help accelerate your next generation antibodies to commercial success.

You won't want to miss a moment of this webinar series focused on 3 primary themes:

Antibody Discovery, Selection and Screening - Monday, June 8
  • Synthetic DNA Technologies Enable Fast and Responsive SARS-CoV-2 Antibody Discovery and Optimization      
  • Drug-like Antibodies Directly from Selections: Specifica’s Generation 3 Antibody Platform     
  • Rapid Discovery of a Diverse Panel of Antibodies Against Membrane Targets using the Beacon® System
         
Learn more
Bispecific Antibodies - Tuesday, June 9
  • Monitoring of Glycosylation using Site Specific Approaches
  • A Bispecific SNIPER™ Demonstrates Preclinical Efficacy Through the Selective Elimination of Tumor Tregs
  • Critical Role of SARS-CoV-2 Spike Protein in Developing Drugs, Serological Tests and Vaccines for COVID-19

Learn more
Computational Approaches and Machine Learning in Antibody and Protein Engineering - Wednesday, June 10
  • Cellular Screening Platforms for Engineering T Cell Receptors and Chimeric Antigen Receptors
  • A Deep Learning Approach to Designing Libraries of Developable Antibodies for Discovery
Learn more

The Future of Antibody Engineering and Therapeutics - eBook Series

Introducing the first in our new Antibody Therapeutics eBook Series. Each edition we will be taking an in-depth look at one area of antibody engineering and therapeutics, and this time we are focusing on how the latest technologies and strategies are shaping the future of the industry.

Highlights:

  • Looking to 2030 Survey Report
  • The response of the antibody therapeutic industry to COVID-19
  • Emerging technologies in antibody engineering and therapeutics
  • Novel technologies and approaches for optimizing antibody discovery